P53 mediated cell motility in H1299 lung cancer cells by Choi, Mi-Yon
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2010
P53 mediated cell motility in H1299 lung cancer
cells
Mi-Yon Choi
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/109
MUTANT P53 MEDIATED CELL MOTILITY IN H1299 LUNG CANCER 
CELLS 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
by 
 
MI-YON CHOI 
Bachelor of Fine Arts James Madison University, 2005 
 
 
Director: DR. ANDREW YEUDALL 
PHILIPS INSTITUTE, VCU SCHOOL OF DENTISTRY 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
August, 2010 
ii 
 Acknowledgement 
First, I would like to acknowledge my advisor, Dr. Andrew Yeudall, for his support and 
guidance.  Thank you for this wonderful opportunity and great learning experience.  I 
also want to acknowledge Dr. Sumitra Deb and Dr. Swati Deb, for their collaboration and 
advice on my research project.  I would like to extend my appreciation to my committee 
members, Dr. Louis De Felice and Dr. Helen Fillmore.  Thanks to Dr. Hiroshi Miyazaki 
for constant support and advice. Thank you, Huixin and Mary Catherine, for all the help 
in the lab and being a good friend.  I thank all our lab members, Steven Christofakis, 
Anna Bulysheva, Christopher Holden, and Dr. Elena Black for support.   
 I would like to also thank my family; mom, dad, and my brother, Ryan Ban for 
their constant support and prayer.  To my husband, Eddie Choi, thank you for your 
patience and support.  And thanks to all my friends in northern Virginia for making my 
breaks exciting and fun. 
iii 
Table of Contents 
Page 
List of Tables ................................................................................................................. vi 
List of Figures ............................................................................................................... vii 
List of Abbreviations .................................................................................................... viii 
Abstract ........................................................................................................................... x 
Chapter 
1 Introduction ................................................................................................... 1 
Cancer ....................................................................................................... 1 
Lung Cancer .............................................................................................. 4 
P53 Protein ................................................................................................ 6 
P53 and Cancer .......................................................................................... 7 
AKT .......................................................................................................... 8 
Nuclear factor- κB ................................................................................... 10 
NFκB and Cancer .................................................................................... 11 
Chemokines ............................................................................................. 12 
Hypothesis ............................................................................................... 14 
Aims of Current Studies ........................................................................... 14 
2 Materials and Methods ................................................................................. 15 
Cell Culture ............................................................................................. 15 
iv 
Cell Lines ................................................................................................ 15 
Antibodies ............................................................................................... 15 
Inhibitors ................................................................................................. 16 
Protein Extraction .................................................................................... 17 
Western Blot ............................................................................................ 17 
Scratch Assay .......................................................................................... 19 
RNA Extraction ....................................................................................... 19 
Agarose Gel Electrophoresis .................................................................... 20 
Reverse Transcription .............................................................................. 20 
Nucleic Acid Quantification..................................................................... 21 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) ............. 21 
MMT Assay............................................................................................. 22 
Statistical Analysis .................................................................................. 22 
3 Results ......................................................................................................... 23 
Effect of Mutant p53 on Cell Motility  ..................................................... 23 
AKT Affects Cell Motility in Cells Expressing Mutant p53 ..................... 27 
Effect of AKT on CXC-Chemokines ....................................................... 30 
Effect of p53 on AKT Phosphorylation .................................................... 32 
NFκB Promotes Cell Motility in Cells Expressing Mutant p53................. 35 
Effect of NFκB on CXC-Chemokines ...................................................... 39 
v 
4 Discussion.................................................................................................... 41 
Aims of Current Studies ........................................................................... 41 
Mutant p53 Enhances Cell Motility .......................................................... 41 
AKT Promotes Motility in Cells Expressing P53 Mutants ........................ 42 
AKT Phosphorylation Can Occur Independently of p53 Mutation ............ 43 
NFκB Promotes Cell Motility in Cells Expressing p53 Mutants ............... 44 
Inhibition of AKT or NFκB Reduce CXCL5-Chemokine Expression ....... 45 
Future Studies .......................................................................................... 47 
Literature Cited ............................................................................................................. 48 
VITA............................................................................................................................. 54 
vi 
List of Tables 
Page 
Table 1: Primary Antibodies for Western Blot. .............................................................. 16 
Table 2: Secondary Antibodies for Western Blot. .......................................................... 16 
vii 
List of Figures 
Page 
Figure 1: Six Properties of Cancer ................................................................................... 2 
Figure 2: P53 Activation in Response to DNA Damage ................................................... 7 
Figure 3: AKT/PI3K Signaling Pathway .......................................................................... 9 
Figure 4: NF-κB Signaling Pathway .............................................................................. 11 
Figure 5:P53 Expression in H1299/D281G, H179L, R175H, R273H, R 248W, and 
Control Cells.. ............................................................................................................... 25 
Figure 6: Expression of Mutant p53 Affects Cell Motility.............................................. 26 
Figure 7: Effects of AKT Inhibitor on Cell Growth in Cells Expressing p53 Mutants. ... 28 
Figure 8: Effect of AKT Inhibitor on Cell Motility in Cells Expressing p53 Mutants. .... 29 
Figure 9: Effect of AKT Inhibitor on CXCL5 Expression. ............................................. 31 
Figure 10: P53, Phosphorylated AKT and Total AKT Expression in Cells Expression 
Mutant p53 .................................................................................................................... 33 
Figure 11: P53, Phosphorylated AKT, and Total AKT Expression in Vector Control. .... 34 
Figure 12: Effects of NFκB Inhibitor on Growth of Cells Expressing p53 Mutants ........ 36 
Figure 13:Phosphorylated NFκB Expression in H1299/D281G, H179L and Vector 
Control .......................................................................................................................... 37 
Figure 14: Effect of NFκB Inhibitor on Motility in Cells Expressing p53 Mutants. ........ 38 
Figure 15: Effect of NFκB Inhibitor on CXCL5 Expression........................................... 40 
viii 
List of Abbreviations 
 
2-mercaptoethanol 2-hydroxyethylmercaptan; β-mercaptoethanol 
ATM   Ataxia Telangiectasia Mutated 
BAD   Bcl-2-associated Death Promotor 
BCA   Bicinchoninic Acid 
Bcl   B- Cell Lymphoma 
BM   Basement Membrane 
BSA   Bovine Serum Albumin 
cDNA   Complementary Deoxyribonucleic Acid 
CDK   Cyclin Dependent Kinase 
DMEM  Dulbecco‘s Modification of Eagle‘s Medium 
DMSO   Dimethyl Sulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP   Deoxyribonucleotide Triphosphate 
ECM    Extracellular Matrix 
EDTA   Ethylenediaminetetraacetic Acid 
EMT   Epithelial to Mesenchymal Transition 
FBS   Fetal Bovine Serum 
FGF   Fibroblast Growth Factor 
GSK3β  Glycogen Synthase Kinase 3β 
IκB   Inhibitor of κB  
MeOH   Methanol 
MDM   Murine Double Minute 
MMP   Matrix Metalloprotease 
mRNA   Messenger RNA 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaCl  Sodium Chloride 
NaOH   Sodium Hydroxide  
NF-κB   Nuclear Factor-κB 
ix 
NSCLC  Non- Small Cell Lung Cancer 
NTC   Non-targeting Control 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PDGF   Platelet- Derived Growth Factor 
PKA   Protein Kinase A 
PKC   Protein Kinase C 
PMSF   Phenylmethylsulfonyl Fluoride 
PVDF   Polyvinylidene Fluoride 
qRT-PCR  Quantitative Real-time PCR 
RB   Retinoblastoma 
RNA   Ribonucleic Acid 
ROS   Reactive Oxygen Species 
SCLC   Small-cell Lung Cancer 
SDS   Sodium Dodecyl Sulphate 
shRNA  Short Hairpin RNA 
TCF   T-cell Factor 
TGF   Transforming Growth Factor 
TNF   Tumor Necrosis Factors 
TRAF   TNF Receptor Associated Factor 
Tris   Tris (Hydroxymethyl) Methylamine 
TTBS   Tween-Tris-Buffered Saline 
Tween 20  Polyoxyethylene(20)sorbitan Monolaura 
uPA   Urokinase-type Plasminogen Activator 
  
x 
 
 
 
Abstract 
 
 
 
MUTANT P53 MEDIATED CELL MOTILITY IN H1299 LUNG CANCER CELLS 
By Mi-Yon Choi, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
Major Director:  Dr. Andrew Yeudall 
Philips Institute, VCU School of Dentistry 
 
 
 
 
Studies have shown that gain-of- function mutant p53, AKT, and NFκB promote 
invasion and metastasis in tumor cells.  Signals transduced by AKT and p53 are integrated 
via negative feedback between the two pathways. Tumor derived p53 was also indicated to 
induce NFκB gene expression.  Due to the close relationship between p53/AKT and 
p53/NFκB, we hypothesized that AKT and NFκB can enhance motility in cells expressing 
mutant p53.  Effects on cell motility were determined by scratch assays. CXCL5- 
chemokine is also known to induce cell motility. We hypothesized that enhanced cell 
motility by AKT and NFκB is mediated, in part, by CXCL5.  CXCL5 expression levels in 
the presence and absence of inhibitors were determined by qRT-PCR. We also 
hypothesized that gain-of-function mutant p53 contributes to the activation of AKT. The 
xi 
effect of mutant p53 on AKT phosphorylation was investigated with a Ponasterone A- 
inducible mutant cell line (H1299/R175H) and vector control.  These results indicated that 
AKT and NFκB enhance motility in cells expressing mutant p53 and this enhanced 
motility is, in part, mediated by CXCL5.  However, AKT phosphorylation was 
independent of mutant p53.   
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Introduction 
 
Cancer 
Each year, cancer is responsible for one-fifth of deaths in the United States and 
100- 350 deaths per 100,000 people worldwide.  Cancer is due to malfunction of 
mechanisms that regulate the growth and proliferation of cells, which transforms normal 
cells into malignant cancer cells.  Almost all cancers are due to genetic damage 
accompanied by influences of tumor-promoting chemicals, hormones, and sometimes virus 
(Lodish, 2004).  Several observations indicated that the genomes of tumor cells are 
invariably altered at multiple sites, suffering disruptions like point mutations and change in 
chromosome complement (Kinzler and Vogelstein, 1996).  Six fundamental cellular 
properties are altered in cancer cells that collectively dictate malignant growth. These six 
hallmarks of cancer are self-sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of apoptosis, limitless replicative potential, tissue invasion and metastasis, 
and sustained angiogenesis (Hanahan & Weinberg, 2000).  Most human cancers share 
these six properties.  
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Figure 1. Six Properties of Cancer 
In normal cells, mitogenic growth signals are required to shift from a quiescent state into a 
proliferative state.  However, cancer cells can generate their own growth signals (e.g. 
PDGF and TGFα) to mimic the normal growth signals, creating autocrine stimulation (Fedi 
et al., 1997).  Antiproliferative signals, including soluble growth inhibitors and 
immobilized inhibitors, found in normal tissue are required to maintain cellular quiescence 
and tissue homeostasis.  Absence of these antiproliferative signals causes quiescent (G0 
state) cells to enter into the G1 phase of the cell cycle.  Based on the environmental signals, 
cells in G1 phase either proliferate, enter into a quiescent state, or enter into an irreversible 
postmitotic state (cell differentiation) (Hanahan & Weinberg, 2000).  These 
antiproliferative mechanisms can be disrupted in a variety of ways in different types of 
human cancer (Lodish, 2004). However, cell proliferation depends on more than avoidance 
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of antiproliferative signals. Cells undergoing multiplication can be instructed to enter into 
the irreversible postmitotic state (terminal differentiation).  Cancer cells can reverse this 
process by overexpressing oncoproteins, such as c-Myc, to impair differentiation and 
promote growth (Kinzler and Vogelstein, 1996). 
 During normal development, many cells are designated for programmed cell death, 
also known as apoptosis.  In response to abnormalities, such as DNA damage, hypoxia, 
and signaling imbalance by oncogene activity, cells can trigger apoptosis (Lodish, 2004).  
The rate of apoptosis also contributes to the ability of tumor cell populations to expand in 
number.   If cells survive with abnormalities by avoiding apoptosis, they will continue to 
grow in number and may contribute to tumor formation.  In cancer cells, apoptosis can be 
avoided in two ways; over expression of antiapoptotic proteins (e.g. Bcl-2, Bcl-XL, and 
Bcl-W) (Hueber et al., 1997) or inactivation of tumor suppressor genes (e.g. p53) 
(Symonds et al., 1994).  Both mechanisms contribute to rapidly growing tumors with low 
numbers of apoptotic cells.   
 All cells in a tissue reside within 100µm of a capillary blood vessel to obtain the 
oxygen and nutrients which are crucial for cell function and survival (Hanahan and 
Weinberg, 2000).  Just like normal cells, tumor cells also require recruitment of new blood 
vessels in order for them to grow to a large mass.   Without a blood supply, tumor cell 
growth is limited to about 10
6
 cells due to division of cells outside the mass balanced by 
death from the center.   These small localized tumors are called benign and closely 
resemble normal cells, without causing any threat to their host (Lodish, 2004).  Previous 
studies have shown that angiogenesis, development of new vessels, was found to be 
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activated prior to becoming a full-blown tumor. Tumors activate the ―angiogenic switch‖ 
by changing the balance of angiogenesis inducers and counteracting inhibitors (Hanahan & 
Folkman, 1996).  Angiogenic growth factors that stimulate formation of new vessels 
include bFGF, TGFα, and VEGF.   The presence of an adjacent blood vessel also 
facilitates the process of metastasis which functions in migration and invasion of distant 
tissues (Folkman, 2002).  90% of human cancer death is caused by this metastatic property 
of cancer cells.  Attracted by signals secreted by macrophages and other cells, cancer cells 
can leave the primary tumor site and reach the blood vessels.   These tumor cells penetrate 
vessel walls by extending ―invadopodia,‖ which produce different proteases to open up a 
pathway (Yamaguchi et al., 2005).  Once they reach the bloodstream, these cancer cells are 
free to move out and colonize in the adjacent tissue, as long as they acquire properties 
mentioned above.   
 
Lung Cancer 
Lung cancer is the leading cause of cancer death in the world.  Approximately 1.2 
million deaths were reported to be due to lung cancer each year and it is still on the rise.  It 
has been shown that the most well- known cause is tobacco use and is responsible for 
about 85% of lung cancer.  Cigarettes contain about 50 known lung carcinogens, which 
can induce genomic damage and alter the defense mechanisms of lung epithelium leading 
to lung cancer (Li, 2009).  However, other causes have been reported, such as occupational 
exposures, infections and genetics (De Matteis, 2008).    Although it is a leading cause of 
death world-wide, it has been shown that the rate of lung cancer is decreasing in the 
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developed countries, mainly due to an effort to decrease smoking.  The histological 
subtype of lung cancer has also shifted from squamous cell carcinoma and small cell lung 
cancer to that of adenocarcinoma.  Unfortunately, the rate of tobacco use and lung cancer 
still remains high in developing countries.  Previous studies have also reported that women 
are more prone to lung cancer than man.  There is no conclusive evidence why more 
women are affected; however, it has been shown that women are less successful in 
smoking cessation.  Men and women are different physiologically, psychologically, and 
behaviorally and it may be necessary to clearly understand the differences and reasons for 
women in initiating smoking as well as quitting smoking in order to decrease the rate of  
lung cancer in women (Toh, 2009). 
Lung cancer can be categorized into small- cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC).  SCLC is a subtype with a neuroendocrine phenotype, whereas 
NSCLC includes adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma 
(Sekido et al., 2003).  Tobacco carcinogens were suggested to cause p53 mutations in lung.  
P53 is a tumor suppressor protein that regulates cell-cycle check point signals, which cause 
the cell to undergo either G1 arrest, DNA repair, or apoptosis (Levine, 1997).  P53 
mutations in lung cancer correlate with tobacco smoking and usually consist of the G-T 
transversions expected from tobacco smoke carcinogens (Greenblatt et al., 1994). About 
70%-80% of the somatic mutations of p53 found in lung cancer are missense and prolong 
the half-life of the mutant p53 protein (Sekido et al., 2003).  Alteration of p53 is observed 
in 75%-100% of SCLCs and 47% of NSCLCs. In NSCLCs, p53 alteration can be seen in 
51% of squamous-cell carcinomas, 54% of large-cell carcinomas and 39% of 
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adenocarcinomas (Tammemagi et al., 1999).  Other pathways controlling the G1 to S phase 
transition of the cell cycle are also shown to be affected in lung cancer, such as p16- cyclin 
D1- CDK4- RB pathway.  P16 mutations have been observed in 30%-70% of NSCLCs, 
whereas inactivation of RB is the preferential mechanism in SCLC.  RB inactivation 
occurs in ~90% of SCLCs and 15%-30% of NSCLCs (Sekido et al., 1998). 
 
P53 Protein 
   p53 is a stress response protein that functions primarily as tetrameric transcription 
factor which regulates genes that control progression through the cell cycle or that initiate 
apoptosis (Brosh and Rotter, 2009).  In response to stress signals, such as DNA damage, 
UV radiation, and hypoxia, wild-type p53 induces growth arrest, DNA repair, or apoptosis 
(Levine, 1997).  In normal resting cells, p53 is extremely unstable and is kept at low level 
by murine double minute 2 (MDM2) protein.  MDM2 binds to p53 protein and induces 
addition of ubiquitin molecules, targeting p53 for proteosomal degradation (Lodish, 2004).  
However, under cellular stress, the p53 protein is rescued from degradation and 
accumulates to high levels (Boehme and Blattner, 2009).  Under stress, cells activate ATM 
or ATR, serine-threonine kinases that phosphorylate MDM2, leading to increase in p53 
concentration. Activated ATM also stabilizes p53 by phosphorylation, permitting p53-
activated expression of genes to induce cell cycle arrest in G1, promote apoptosis, or 
participate in DNA repair. Among the genes activated by p53 are pro-apoptotic proteins 
such as Bax (Lane, 2005). 
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Figure 2. P53 Activation in Response to DNA Damage 
 
P53 and Cancer 
P53 is one of the most commonly mutated genes and it is seen in greater than 50% 
of all human cancers (Harris, 1996).  The majority of cancer associated mutations in p53 
are monoallelic missense mutations within the central DNA- binding domain, which 
usually lead to expression of highly stable mutant protein, incapable of activating wild-
type p53 target genes.  Besides losing their wild-type activity, many p53 mutants also 
function as dominant negative proteins that inactivate wild-type p53 expression from the 
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remaining wild-type allele by hetero-oligomerization.  However, an increasing number of 
studies suggest that many p53 mutants not only lose their tumor suppressive function, but 
also gain new oncogenic properties that are independent of wild-type p53, known as ‗gain-
of-function‘ (Brosh and Rotter, 2009).  P53 null cells transfected to express mutant p53 
have a growth advantage compared to vector control (Scian et al, 2004).  Other studies 
have shown that mutant p53 mediates upregulation of genes that are important in cell 
survival such as ASNS, hTERT, and NFκB2 (Scian et al, 2004) (Scian et al, 2005).  
Mutant p53s also gain new oncogenic properties by interacting with p73 and p63, which 
are known as p53 family members.  Mutant p53 binding with p73 and p63 consequently 
inhibits their ability to induce cell-cycle arrest (Brosh and Rotter, 2009).   
 
AKT 
AKT, also known as protein kinase B (PKB), is a serine/threonine kinase that 
regulates many biological processes, such as proliferation and apoptosis.  Activated AKT 
can directly phosphorylate several components of the cell-death machinery, such as BAD, 
caspase-9, and FKHR.  BAD is a member of the Bcl2 family of proteins that promotes cell 
death by forming hetero-dimers with the survival factor BCL-X.  AKT phosphorylation of 
BAD prevents BAD/BCL-X interaction, restoring BCL-X‘s anti-apoptotic function (Datta 
et al., 1997).  Caspase-9, a pro-apoptotic protease, also gets inactivated through direct 
phosphorylation by AKT (Cardone et al., 1998).  AKT can also influence cell survival by 
indirectly affecting two central regulators of cell death, nuclear factor κB (NF-κB) and 
p53.  NF-κB is a transcription factor complex that promotes cell survival in response to 
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apoptotic stimuli.  AKT positively affects NF-κB activity by phosphorylation and 
activation of IκB kinase, which induces degradation of IκB.  Dissociation of NFκB from 
IκB allows NFκB to translocate to the nucleus and activate target genes (Kane et al., 1999).  
AKT can also phosphorylate MDM2, which enhances the translocation of MDM2 to the 
nucleus.  Increased MDM2 translocation to the nucleus will increase p53 degradation 
which, in turn, promotes cell survival (Mayo and Donner, 2001).   
 
Figure 3. AKT/PI3K Signaling Pathway 
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Nuclear Factor-κB 
 Nuclear factor-κB protein complex is a ubiquitous transcription factor that controls 
the expression of genes involved in immune responses, apoptosis, and cell cycle.  The 
mammalian NFκB family consist of 5 members; NFκB1 (p50/p105), NFκB2 (p52/p100), 
c-Rel, RelA (p65) and RelB (Lee et al., 2007).  NF-κB protein exists in unstimulated cells 
as homo- or heterodimers bound to IκB protein, an inhibitory factor of NF-κB.  NF-κB has 
a highly conserved 300 amino acid Rel homology domain that is located near N-terminus 
of the protein.  This highly conserved domain is responsible for DNA binding, 
dimerization, and interaction with IκB protein (Baldwin, 1996).  Dimerization with IκB 
sterically blocks NF-κB‘s nuclear localization sequence, causing cytoplasmic localization 
of the protein complex (Siebenlist et al., 1994).  When external stimuli, such as infectious 
agents or inflammatory cytokines, are present, I-κB kinase becomes activated and 
phosphorylates two critical serine residues in the N- terminal regulatory domain of IκB.   
This phosphorylation by IκB kinase targets IκB for rapid polyubiquitination and 
subsequent degradation by the proteosome (Senftleben and Karin, 2002).  Dissociation 
from IκB allows NF-κB to expose nuclear- localization sequence and translocate into 
nucleus.  In the nucleus, NF-κB regulates the transcription of diverse genes encoding 
cytokines, growth factors, cell adhesion molecules and pro/antiapoptotic proteins (Lodish, 
2004). 
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Figure 4. NF-κB Signaling Pathway 
 NF-κB is continuously activated in a number of solid tumors.  Some of the reasons 
for sustained NF-κB activity include abnormal IκB activity and shorter half-life of IκB 
(Garg and Aggarwal, 2002).  Several oncogenes, including ras and myc, require NF-κB to 
induce abnormal cell proliferation and tumorigenesis (Jong et al., 2000).   
 
NFκB and Cancer 
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 Studies have shown that NFκB is activated in a number of hematologic and solid 
tumors. The activation of NFκB is necessary for the transforming ability of several cellular 
oncoproteins (Lee et al., 2007).  Several oncogenes, such as ras, bcr-abl and myc, can 
activate NFκB.  NFκB is required for the H-ras oncogene to induce cell proliferation and 
tumorigenesis (Jong et al., 2000).  NFκB suppresses apoptosis by enhancing the expression 
of multiple anti-apoptotic proteins and interferes with the expression or activity of 
proapoptotic proteins.  The anti-apoptotic proteins regulated by NFκB include inhibitor of 
apoptosis proteins (IAPs) 1 and 2, Bcl-XL, Bfl-1, TNF receptor associated factor 1 (TRAF) 
and TRF2 (Kucharczak et al., 2003).  Proapoptoic genes that are upregulated by NFκB 
include Fas/CD95, FasL, death receptor 4 (DR4) and DR5 (Lee et al, 207).  NFκB is also 
indicated to destabilize p53 by enhancing MDM2 expression, interfering with p53 induced 
apoptosis (Tergaonkar et al., 1998).  NFκB plays an important role in tumor invasion and 
metastasis by regulating matrix metalloproteinase 2 (MMP2), MMP9, and serine protease 
urokinase-type plasminogen activator (uPA) (Lee et al., 2007).  Intercellular adhesion 
molecule 1 and vascular cell adhesion molecule 1, that are associated with metastasis, are 
also regulated by NFκB (Johnson, 1999).  NFκB also promotes cell cycle progression by 
regulating expression of genes, such as cyclin D1, D2,D3 and c-myc, that are involved in 
the cell cycle machinery (Lee et al., 2007). 
 
Chemokines 
Chemokines are a superfamily of small cytokine-like molecules that induce 
directed chemotaxis in nearby responsive cells.  They function mainly as chemoattractants 
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for leukocytes, monocytes, neutrophils, and other effector cells from the bloodsteam to 
sites of infection.  Some chemokines are also identified as key regulators of lymphocyte 
development, migration, and angiogenesis.  Chemokines interact with seven 
transmembrane-spanning G-protein-coupled receptors (GPCR) and they can be released by 
many different types of cells (Janeway, 2005).  Chemokines are subclassified into four 
subfamilies; CC, CXC, XC, and CX3C (Zlotnik and Yoshie, 2000). The CXC chemokines 
are further subdivided into ELR
+
 and ELR
-
 based on the presence or the absence of the 
motif glu-leu-arg (ELR) preceding the CXC sequence (Raman et al., 2007).  ELR
+
 CXC 
chemokines, such as CXCL5 and CXCL8, induce the migration of neutrophils, and 
stimulate endothelial cell migration during angiogenesis, whereas ELR
-
 CXC chemokines 
target lymphocytes (Frederick and Clayman, 2001).  The CC chemokines act on subsets of 
dendritic cells, lymphocytes, macrophages, eosinophils, and natural killer cells. However, 
CC chemokines do not stimulate neutrophils (Raman et al, 2007).        
 The secretion of the chemokines and the cell surface expression of the chemokine 
receptors on tumor cells play critical roles in facilitation of tumor growth and/ or 
metastasis (Raman et al, 2007).  Studies have shown that CXC chemokines play a most 
extensive role in angiogenesis out of the four families of chemokines. Early evidence 
suggested that ELR
+
 CXC chemokines, such as CXCL5 and CXCL8, stimulate endothelial 
cell migration, proliferation, and angiogenesis in vivo (Raman et al, 2007). However, 
recent studies have shown that the ELR
-
 chemokine CXCL12 and its receptor CXCR4 can 
both increase angiogenesis and play an important role in metastatic progression (Orimo 
and Weinberg, 2006). 
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Hypothesis 
AKT and NFκB promote motility and CXCL 5 expression in cells expressing gain-
of-function mutant p53.   P53 also promotes the phosphorylation of AKT. 
 
Aims of Current Studies 
 To determine the effect of AKT on motility in cells expressing gain-of-function 
p53. 
 To determine the effect of AKT on chemokine expression in cells expressing gain-
of-function p53. 
 To determine the effect of gain-of-function mutant p53 on AKT phosphorylation 
 To determine the effect of NFκB on motility in cells expressing gain-of-function 
p53. 
 To determine the effect of NFκB on chemokine expression in cells expressing gain-
of-function p53. 
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Materials and Methods 
 
Cell Culture 
H1299 lung cancer cells were cultured in Dulbecco‘s Modification of Eagle‘s 
Medium (DMEM) (4500 mg/L D-Glucose, L-Glutamine and 110 mg/L sodium pyruvate) 
(Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS) and penicillin-streptomycin 
(10 µg/ml) (Invitrogen, Carlsbad, CA) as an antibiotic. The cells were maintained in a 
37
o
C humidified incubator with 90% air and 10% CO2.  
 
Cell Line 
To examine the gain-of-function effect of mutant p53, H1299 cells were used. 
H1299 is a p53-null human lung carcinoma cell line. Stable cell lines were generated by 
transfecting H1299 cells using the calcium phosphate method with either pCMV- Neo 
Bam p53-D281G or vector alone (Scian et al., 2004). Several clones from each transfection 
were expanded into cell lines. Cell lines that were selected for these experiments were; 
H1299-control 5 (HC -5), H1299-p53-D281G, H1299-p53-R273H, H1299-p53-R175H, 
H1299-p53-H179L, H1299-p53-R248W (Scian et al, 2004). 
 
Antibodies 
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Antibody recognizing phospho-Akt (Ser473) was purchased from Cell Signaling 
Technology, Inc. (Danvers, MA). Antibody for Akt1 was purchased from BD Biosciences, 
Pharmingen (Mississauga, ON Canada).  p53 (DO-1) monoclonal antibody (sc-126) was 
purchased from Santa Cruz Biotechnologies, Inc., (Santa Cruz, CA). Antibody that 
recognizes actin (sc-1616) was purchased from Santa Cruz Biotechnologies Inc. (Santa 
Cruz, CA).  Horseradish peroxidase-conjugated anti-goat, anti-rabbit and anti-mouse 
secondary antibodies were obtained from MP Biomedical (Aurora, OH). 
Primary Antibody Supplier Dilution 
P53 (DO-1) Santa Cruz Biotechnology, 
Santa Cruz, CA 
1:1000 
Phospho-AKT Cell Signaling Technology, 
Inc. 
Danvers, MA 
1:1000 
AKT1 BN Biosciences, Pharmingen 
Mississauga, ON Canada 
1:1000 
Actin Santa Cruz Biotechnology, 
Santa Cruz, CA 
1:1000 
Table 1: Primary Antibodies for Western Blot 
Secondary Antibody Supplier Dilution 
Horseradish 
peroxidase0conjugated anti-
goat 
MP Biomedical 
Aurora, OH 
1:10,000 
Anti- rabbit MP Biomedical 
Aurora, OH 
1:15,000 
Anti- mouse MP Biomedical 
Aurora, OH 
1:10,000 
Table 2: Secondary Antibodies for Western Blot 
 
Inhibitors 
17 
AKT inhibitor from Calbiochem (Cat # 124005) (Darmstadt, Germany) was used at 
20µM working concentration.  NF-κB inhibitor from Calbiochem (Cat # 4814056) 
(Darmstadt, Germany) was prepared in DMSO as a stock solution of 2mM and used at 
2µM. 
 
Protein Extraction. 
Cells were cultured to ~90% confluence on a 60 mm plate. Medium was aspirated 
from the plate and the cells were washed with PBS.  After the PBS was aspirated, 100µl of 
lysis buffer (1M HEPES pH 7.5, 0.5M EGTA pH 8.0, 100mM β-glycerophosphate, 5 mL 
NP-40 lysis buffer, 2M MgCl2) was added to each plate.  0.1M PMSF (10μl/ml LB), 
leupeptin (1μl/ ml LB), aprotinin (1µl/ml LB), 1M DTT (1μl/ml LB), and 1M 
orthovanadate (2µl/ml LB) were added to the lysis buffer before it was added to the plates. 
Plates were placed on ice for 10 minutes with occasional rocking to distribute the lysis 
buffer evenly. Cells were then scraped with a cell lifter to one edge of the plate and the 
lysates were transferred to a 1.5 ml microcentrifuge tube.  The lysates were centrifuged at 
10,400 x g at 4º C for 10 min and the supernatant was carefully transferred to a new tube, 
discarding the pellet. The lysates were quantified spectrophotometrically, using the Biorad 
BCA Protein Assay Reagent (Bio-Rad Laboratories, Hercules, CA) at 600 nm and were 
compared to a standard curve of known quantities of bovine serum albumin (BSA). Protein 
was stored at -20 C. 
 
Western Blot 
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30-80μg of protein lysates were loaded onto 10% denaturing polyacrylamide gels 
(Sambrook & Russell, 2001). Lysates were resolved for 1.5h at 120 V in 1X SDS-PAGE 
running buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 70 mM EDTA, 2% SDS).  The 
protein was then transferred from gel to PVDF membrane (Immobilon-P; Millipore Corp., 
Bedford, MA) for 16-20 h in 1x transfer buffer (20mM pH 7.9, 100mM NaCl, 70mM 
EDTA, and 20% MeOH). The membrane was placed in 100% MeOH for several minutes 
and was air dried completely. The membrane was then re-wet in100% MeOH, for several 
minutes and was rinsed in T-TBS (0.05% Tween-TBS).  5% non-fat dried milk in T-TBS 
was used to block the membrane for 1h at room temperature on the shaker. The membrane 
was rinsed once with T-TBS and was placed in the primary antibody solution. To probe for 
p53, AKT and actin, the primary antibody was diluted to 1:1000 in 5% milk in T-TBS and 
was incubated in room temperature on the shaker for 1 h. To probe for p-AKT, the primary 
antibody was diluted to 1:1000 in 5% BSA in T-TBS at 4ºC on the shaker overnight. After 
the primary antibody, the membrane was washed with T-TBS 6 times for 3 min each.  
Secondary antibody for p53 (anti-mouse) and actin (anti-goat) was diluted to 1:10,000 in 
5% milk in T-TBS and was incubated at room temperature on the shaker for 1h. Secondary 
antibody for p-AKT (anti-rabbit) and AKT (anti-rabbit) was diluted to 1:15,000 in 5% milk 
and was incubated at room temperature on the shaker for 1 h. After the secondary 
antibody, membranes were washed with T-TBS, 6 times for 3min each. The membrane 
was incubated with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer 
Life Sciences Inc., Boston, MA) for 1 min at room temperature and was exposed to x-ray 
film. 
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Scratch Assay 
Cells were plated in triplicate in 12-well plates (Greiner Bio-One, Monroe, NC) at a 
concentration of  5x10
5
 cells/well.  After the cells were grown to 100% confluence, 
medium was aspirated from each well, and cells were washed with PBS.  Each well was 
scratched once vertically with the tip of a sterile pipette tip.  The width of scratch was 
measured in three different locations of each well using a light microscope and AxioVision 
software.  The plates were then incubated at 37 C with 90% air and 10% CO2.  After 10-
16 hours of incubation, the width of the scratch was measured again at the same location.  
The distance cells migrated into the scratch was calculated as a function of time in order to 
obtain the motility rate. 
 
RNA Extraction 
Cells were plated on 60 mm round plates and cultured in DMEM with 10% FBS to 
70-80% confluence. Medium was removed and cells were incubated in 1ml of TRIzol 
(Invitrogen) for 5 min at room temperature. Contents were transferred to the sterile 1.5 ml 
microcentrifuge tube and 200 µl chloroform per 1 mL TRIzol was added. The tube was 
shaken vigorously for 15 sec and was centrifuged at 12,000 x g for 15 min at 4 C.  The 
upper aqueous phase was carefully extracted and transferred to new sterile microcentrifuge 
tube.  To precipitate RNA 500 µL of isoprophyl alcohol per 1mL TRIzol was added to the 
aqueous phase and was inverted several times to mix.  The samples were incubated at 
room temperature for 10 min and centrifuged at 12,000 x g for 10 min at 4 C.  
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Supernatant was removed and 1 mL of 75% ethanol per 1mL TRIzol  was added to wash 
the RNA.  The sample was mixed by vortex and was centrifuged at 12,000 x g for 10 min 
at 4 C.  After the wash, ethanol was removed and the RNA pellet was air-dried for 5-10 
min. The RNA pellet was then dissolved in RNase-free H2O by gently pipetting and was 
incubated for 10 min at 55 to 60 C. RNA was stored at -80 C until use. 
Agarose Gel Electrophoresis 
To test the quality of RNA, 1% agarose gel was prepared with 0.5 g agarose (ISC 
BioExpress, Kayesville, UT) in 50 mL 1x TAE buffer (40 nM Tris, 20 mM glacial acetic 
acid, 10 mM EDTA pH 8.0).  1 g RNA sample was loaded with 6x Ficoll loading buffer, 
and run on the gel for 20-30 minutes at 120V.  5µL Hyperladder marker I (Bioline, 
Taunton, MA) was also loaded on the gel. The RNA was visualized by UV 
transillumination. 
 
Reverse Transcription 
2 μg RNA was added to a nuclease-free microcentrifuge tube, with 1 μL of 100μM 
oligo(dT), 1 μL 10mM dNTP, 1 μL oligo(dT) primer, and sterile, distilled nuclease-free 
H2O up to 13 μL in total.  The mixture was incubated for 5 min at 65 C and was chilled on 
ice for 5 min. After briefly centrifuging, 4 μl 5X First-Strand Buffer (250 mM Tris-HCl, 
pH 8.3) and 2 μL 0.1 M DTT were added.  The contents were mixed gently, and incubated 
in a 42º C water bath for 2 min. 1 μL (200 u/μL) SuperScript II RT (Invitrogen, Carlsbad, 
CA) was added and mixed with gentle pipetting. The mixture was centrifuged briefly to 
collect the contents at the bottom of the tube and was incubated in a 42º C water bath for 
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50 min.  The reaction was inactivated by heating at 70º C for 15 min. cDNA was stored at -
20º C until use. 
 
Nucleic Acid Quantification 
Nucleic acids were quantified using the Thermo Scientific NanoDrop
TM
 1000 
Spectophotometer (Thermo Fisher Scientific, Wilmington, DE). 1 µL ddH20 was loaded as 
a blank, and subsequently 1 µl sample was loaded in order to measure nucleic acid 
concentration.  
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Quantitative real- time polymerase chain reaction (qRT-PCR) was performed using 
an ABI 7500 Fast System (Applied Biosystems, Rockville, MD) and a SYBR green-based 
procedure. A master mix containing 5% primers, 35% ddH2O and 50% ABsolute SYBR 
Green ROX Mix (ABgene, Epsom, Surrey, UK) was made for each gene target to be 
analyzed.  9µl of master mix was added to each well of the 96-well plate (Applied 
Biosystems, Foster City, CA) to get the desired target to a total volume of 10 μl. 1 μl of 
cDNA was added to each triplicate well and 1µl of ddH2O was added to one well as a non-
template control (NTC).  1 L of standards was also added to provide a standard curve.  To 
generate standards, serial dilutions were made using previously generated PCR products.  
The 96-well plate was then sealed with optical cover and inserted into the 7500 Fast Real-
Time PCR System and the qRT-PCR was carried out using the SYBR green-protocol. 
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MTT Assay 
 Cells were plated at 2x10
4
 cells per well in triplicate in a 12-well plate and allow to 
grow for 24 h.  100 μL of MTT reagent (3-(4,5-Dimethylthiazolyl-2)-2,5-Diphenyl 
Tetrazolium Bromide in PBS) (MP Biomedicals Inc., Solon, OH) was added to each well, 
and the cells were incubated for 4 h at 37°C in 90% air and 10% CO2. The medium and 
reagent were removed from each well, and the formazan crystals were solubilized in 1 mL 
of MTT solubilization buffer (0.01M HCl with 10% SDS) and incubated overnight at 
37°C. Absorbance was measured spectrophotometrically at 570 nm. The MTT 
solubilization buffer was used as the blank measurement. 
 
Statistical Analysis 
Data were analyzed using Microsoft Excel and Graphpad QuickCalcs software 
(http://www.graphpad.com/quickcalcs/).  Paired T-tests were performed, and p-values 
were compared.  An α-value of 0.05 was considered statistically significant. Error bars on 
the figures represent the standard error of the mean. 
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Results 
 
Effect of Mutant p53 on Cell Motility  
Previous studies have shown that cells expressing mutant p53 possess a selective 
growth advantage over those expressing wild-type p53 (Levine, 1997).  It is also known 
that mutant p53 promotes cell proliferation (Scian et al., 2004). Our goal was to examine 
gain-of-function mutant p53 and its role in cell motility.  To examine the gain-of-function 
effect of mutant p53 on cell motility, we used the stably transfected H1299 cell lines.  
H1299 is a human lung cancer cell devoid of endogenous p53.  These cells were 
transfected to stably express different mutant p53; R248W, R175H, D281G, H179L, 
H273H (Scian et al., 2004).  To confirm the stable mutant p53 expression we prepared 
protein lysates from each cell line and performed western blot.  As expected (Figure 5), all 
of the transfected cell lines stably express mutant p53. We can also see that the HC5 
control cell line transfected with empty vector does not express p53.  To examine if mutant 
p53 plays a role in cell motility, scratch assays were performed.  After cells were grown to 
100% confluence, a scratch was made using sterile pipette tip.  The width of the scratch 
was measured using a light microscope and was noted as 0 h.  After allowing the cells to 
migrate for 10 h under standard conditions, the width was measured at the same location 
and the rates were calculated (Figure 6).  Compared to the vector control (HC5), most cell 
lines expressing mutant p53 had a higher motility rate (Figure 6).  However, the motility 
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rate varied between cell lines expressing different mutants.  D281G showed the highest 
rate (~70µm/hr), whereas the rate of R248W was close to that of the vector control. Cells 
expressing p53-D281G and H179L were selected for the further experiments.          
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Figure 5: P53 Expression in H1299/D281G, H179L, R175H, R273H, R 248W, and 
Control Cells.  Cells were counted and plated in a 6-well plate and were allowed to grow 
over night.  Lysates were collected as described in ‗Methods,‘ and were analyzed for 
mutant p53 expression using western blot.  Actin was used as a loading control.     
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Figure 6: Expression of Mutant p53 Affects Cell Motility. Cells were counted and 
plated in triplicate in 12-well plates and incubated under standard conditions for overnight.  
Scratch assay was performed as described in ‗Methods,‘ and width was measured using a 
light microscope.  
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AKT Affects Cell Motility in Cells Expressing Mutant p53 
To examine the effect of AKT on cell motility in mutant p53 cells, a chemical AKT 
inhibitor was used.  MTT assay was performed to determine the appropriate concentration 
of AKT inhibitor to use without being toxic to the cells (Figure 7).  Both of the p53 mutant 
expressing cell lines (D281G and H179L) and vector control were viable in 1 µM and 20 
µM concentration of AKT inhibitor.  20 µM concentration of AKT inhibitor was used in 
our experiment to maximize the inhibitory effect.  After selecting the proper concentration 
to use, scratch assays were performed to examine the effect of AKT on cell motility in the 
presence and absence of AKT inhibitor.  Cells were pre-incubated with AKT inhibitor for 
24 h prior to scratch.  As a control, cells were incubated in DMSO in an equivalent volume 
to AKT inhibitor.  Figure 8 shows that the cells in the absence of AKT inhibitor migrate at 
a faster rate compared to cells in the presence of AKT inhibitor.  A similar trend can be 
seen in both mutant P53-expressing cell lines; D281G and H179L.           
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Figure 7: Effects of AKT Inhibitor on Cell Growth on Cells Expressing p53 Mutants.  
Cells were counted and were plated in triplicate in 12-well plates and incubated in the 
indicated concentrations of AKT inhibitor. After 24 hours of incubation MTT assay was 
performed as described in ‗Methods.‘ Absorbance was measured in a spectrophotometer at 
570 nm. 
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Figure 8: Effect of AKT Inhibitor on Cell Motility in Cells Expressing p53 Mutants. 
Cells were counted and plated in triplicate in 12-well plates in the presence and in the 
absence of AKT inhibitor (20 μM).  After 24 hours of incubation, scratch assays were 
performed as described in ‗Methods,‘ and width was measured using light microscope.   
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Effect of AKT on CXC-Chemokines 
Previous studies using H1299 cells expressing mutant p53 D281G indicated that 
inhibition of CXCL5 expression results in decreased cell motility (Yeudall et al., 
submitted).  Our data had shown that cell motility was reduced by inhibiting AKT (Figure 
8).  It is possible that the effect of AKT on cell motility is mediated by CXC-chemokines.  
To investigate the effect of AKT on CXC-chemokine expression, qRT-PCR was 
performed using H1299 cells expressing D281, H179L, and vector control.  Cells were 
pre-incubated with AKT inhibitor for 24 h prior to RNA extraction.  After performing 
reverse transcription, qRT-PCR was performed on the cDNA template using CXCL5-
specific primers.  Figure 9 shows that in the presence of AKT inhibitor, CXCL5 expression 
is reduced in both of the mutant cell line (D281G and H179L). 
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Figure 9: Effect of AKT Inhibitor on CXCL5 Expression.  RNA was extracted and 
reverse-transcription was performed to create cDNA as described in ‗Methods‘. cDNA was 
quantified by qRT-PCR.  The relative expression ratio represents expression of CXC5 to 
the internal standard, γ-tubulin.     
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Effect of p53 on AKT Phosphorylation 
Studies have shown that activated AKT can directly phosphorylate components of 
the cell-death machinery, such as BAD and caspase-9 (Datta et al., 1997).  In the presence 
of mutant p53, tumor suppressor function is lost and cell survival increases (Brosh and 
Rotter, 2009).   It is possible that the cells expressing mutant p53 possess a selective 
growth advantage through effects on AKT.  To investigate the effect of p53 on AKT 
phosphorylation, H1299 cells containing Ponesterone A- inducible, mutant p53-R175H  
were used. In the presence of Ponasterone A, mutant p53-R175H is expressed.  Cells were 
incubated in the presence and in the absence of Ponasterone A over the following time 
course; 24 h, 48 h, 72 h, 96 h, and 120 h.  100% ethanol (solvent for Ponasterone A) was 
used as a control for the uninduced cells.  Lysates were collected and western blotting was 
performed to determine p53, phosphorylated AKT and total AKT expression.  Figure 10 
shows that only the cells that were exposed to Ponasterone A expressed mutant p53.  
Expression of phosphorylated AKT and the total amount of AKT both increased over time 
up to 96 h in the induced cells.  However, we also noticed that expression of 
phosphorylated AKT and total AKT in uninduced cells increased over time in a similar 
manner.  We carried out a similar experiment using the control cell that contained empty 
vector which does not express mutant p53.  Figure 11 shows the increase in 
phosphorylated AKT and total AKT expression over time in both induced and uninduced 
control cells.  Actin was used as a loading control.  
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Figure 10: P53, Phosphorylated AKT and Total AKT Expression in Cells Expressing 
Mutant p53.  Cells were counted and plated in 60 mm round plates and were allowed to 
grow in the absence (-) or presence (+) of Ponasterone A for the indicated times.  Lysates 
were collected as described in ‗Methods,‘ and were analyzed for mutant p53, 
phosphorylated AKT and total AKT expression using western blot.  Actin was used as a 
loading control.     
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Figure 11: P53, Phosphorylated AKT, and Total AKT Expression in Vector Control. 
Cells were counted and plated in 60 mm round plates and were allowed to attach 
overnight.  Cells were grown in the absence (-) or presence (+) of Ponasterone A for the 
indicated times.  Lysates were collected as described in ‗Methods,‘ and were analyzed for 
mutant p53, phosphorylated AKT and total AKT expression using western blot.  Actin was 
used as a loading control.     
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NFκB Promotes Cell Motility in Cells Expression Mutant p53 
NFκB is known to regulate the transcription of diverse genes encoding growth 
factors and pro/antiapoptotic proteins.  Our goal was to explore the effect of NFκB on the 
motility of cells expressing mutant p53.  As in studies using the AKT inhibitor, H1299/ 
D281G and H1299/H179L were used for this experiment. MTT assay was performed to 
determine the appropriate concentration of AKT inhibitor to use without being toxic to the 
cells (Figure 12).  Both of the p53 mutant cell lines (D281G and H179H) and vector 
control showed that cells were viable in all three concentration of NFκB inhibitor (20 nM, 
200 nM, and 2 µM).  2 µM concentration of NFκB inhibitor was used in our experiment to 
maximize the inhibitory effect.  We performed a western blot to determine if the inhibitor 
is working as expected. We can see that in the presence of NFκB inhibitor, expression of 
phosphorylated NFκB is reduced compared to the controls (Figure 13).  After selecting the 
proper concentration to use, scratch assays were performed to examine the effect of NFκB 
on motility in cells expressing p53 mutants.  Scratch assays were carried out in the 
presence and absence of NFκB inhibitor. Figure14 shows that the cells in absence of NFκB 
inhibitor migrate at a faster rate compared to cells in the presence of NFκB inhibitor. A 
similar trend can be seen in both of the p53 mutant cell lines and vector control, although 
the magnitude of the reduction was less in control cells. 
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Figure 12: Effects of NFκB Inhibitor on Growth of Cells Expressing p53 Mutants. 
Cells were counted and were plated in triplicate in 12-well plates and incubated in different 
concentrations of NFκB inhibitor as indicated.  After 24 hours of incubation MTT assay 
was performed as described in ‗Methods.‘ Absorbance was measured in a 
spectrophotometer at 570 nm. 
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Figure 13: Phosphorylated NFκB Expression in H1299/D281G, H179L and Vector 
Control. Cells were counted and plated in a 6-well plate in the presence and absence of 
NFκB inhibitor and were allowed to incubate for 24 hours.  Lysates were collected as 
described in ‗Methods,‘ and were analyzed for phosphorylated NFκB expression using 
western blot.  Actin was used as a loading control.  
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Figure 14: Effect of NFκB Inhibitor on Motility of Cells Expressing p53 Mutants. 
Cells were counted and plated in triplicate in 12-well plates in the presence and absence of 
NFκB inhibitor (2 μM).  After 24 hours of incubation, scratch assays were performed as 
described in ‗Methods,‘ and width was measured using light microscope.
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Effect of NFκB on CXC-Chemokines 
It has been suggested that NFκB and CXC-chemokines enhance the migratory 
phenotype in cells expressing mutant p53 (Figure 14) (Miyazaki et al., 2006).  It is possible 
that the effect of NFκB on cell motility is mediated by CXC-chemokines.  To investigate 
the effect of NFκB on CXC-chemokine expression, qRT-PCR was performed.  H1299 
cells expressing mutant p53 D281G, H179L and vector control were pre-incubated in the 
presence and absence of NFκB inhibitor for 24hours prior to RNA extraction.  After 
performing reverse transcription, qRT-PCR was performed on the cDNA template using 
CXCL5-specific primers.  Figure 15 shows that in the presence of AKT inhibitor, CXCL5 
expression is reduced in both of the mutant p53-expressing cell lines (D281G and H179L). 
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Figure 15: Effect of NFκB Inhibitor on CXCL5 Expression. RNA was extracted and 
reverse-transcription was performed to create cDNA as described in ‗Methods‘. cDNA was 
quantified by qRT-PCR.  The relative expression ratio represents expression of CXCL5 to 
the internal standard, γ-tubulin. 
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Discussion 
Aims of Current Studies 
The aims of this study were to determine the effect of AKT and NFκB on cell 
motility and CXCL5 expression in cells expressing gain-of function mutant p53.  We also 
examined the effect of mutant p53 on AKT phosphorylation.  
 
Mutant p53 Enhances Cell Motility 
  Studies had shown that mutant p53 not only has a dominant negative effect over 
wild- type p53, but can also gain new oncogenic properties that are independent of wild-
type p53 (Brosh and Rotter, 2009).  Elevated expression of gain-of-function p53 mutants 
enhances the invasive phenotype (Dong et al., 2009) and mediates cell survival (Wee et al., 
2009).  It was also indicated that wild-type p53 regulates cell motility by suppressing 
phosphatidylinositide 3- OH kinase and Rac 1 signaling pathways (Guo et al., 2004).  
Therefore, our focus was to determine the effect of gain-of-function p53 mutants on cell 
motility, which is a key property in metastatic cells. P53 null H1299 human lung cancer 
cells were previously transfected to express different mutant p53 proteins; R248W, 
R175H, D281G, H179L, H273H (Scian et al., 2004).  To examine if mutant p53 plays a 
role in cell motility, scratch assays (wound closure) were performed.  We found that most 
cells that stably express p53 mutants showed a higher motility rate compared to HC5 
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(vector control) cells.  This indicates that mutant p53 expressed in H1299 cell contributes 
to enhanced motility.     
 
AKT Promotes Motility in Cells Expressing p53 Mutants 
 AKT has been implicated as a major factor in many types of cancer. AKT regulates 
many biological processes, such as proliferation and apoptosis (Vivanco and Sawyers, 
2002).  Other studies have shown that AKT can be activated downstream of G-protein 
coupled receptors, and plays an important role in angiogenesis (Sodhi et al., 2004).  Recent 
studies suggest that AKT plays an important role in metastasis by effecting epithelial-to-
mesenchymal transition (EMT).  EMT is the process where epithelial cells become 
migratory and invasive by detaching from their normal surroundings and adopt the 
phenotype of mesenchymal cells.  Common features of tumor EMT include remodeling of 
the cytoskeleton, reduced cell-to-cell adhesion, and increased motility and invasiveness 
(Sheng et al., 2009).  Signals, such as TGF-β, FGF, and oncogenic proteins, lead to 
increased EMT by switching on the transcription factors that down-regulate E-cadherin, 
increase β-catenin, and promote Rac and Rho-dependent cell motility (Thiery, 2002).  
AKT is thought to influence the transcriptional activity of β-catenin by directly 
phosphorylating it on Ser-552 (Fang et al., 2007).  In addition, AKT also down-regulates 
GSK-3β which triggers the degradation of β-catenin.   β-catenin in complex with E-
cadherin plays a role in cell-to-cell adhesion; however this function is lost when β-catenin 
disassociates from E-cadherin (Sheng et al., 2009).   Accumulated β-catenin in the nucleus 
causes increased proliferation and carcinogenesis by β-catenin interacting with T cell 
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Factor (TCF) (Du et al., 2009).  Other studies have shown that AKT can promote basement 
membrane (BM) degradation and extracellular matrix remodeling (EMC) by AKT 
downstream effectors such as matrix metalloproteinase-9 (MMP-9) and urokinase-type 
plasminogen activator (uPA) (Sheng et al., 2009). It is possible that mutant p53 enhances 
tumor progression by means of the AKT signaling pathway.  Here, scratch assays showed 
that cells incubated with AKT inhibitor had decreased motility compared to cells without 
AKT inhibitor. This suggests that effect of gain-of-function mutant p53 on cell motility is 
partly due to the activation of AKT. 
 
AKT Phosphorylation Can Occur Independently of p53 Mutation 
The p53 tumor suppressor protein and AKT play important roles in the transduction 
of proapoptotic and anti-apoptotic signals, respectively (Lim et al., 2009; Vivanco and 
Sawyers, 2002).  Signals transduced by AKT and p53 are integrated via negative feedback 
between the two pathways (Gottlieb et al., 2002).  The p53-AKT network was predicted to 
have all-or-none switching behavior between an anti-apoptotic state (low p53 and high 
AKT levels) and a pro-apoptotic state (high p53 and low AKT levels) (Wee et al., 2009).  
AKT is thought to influence activity of p53 through phosphorylation of the p53- binding 
protein, MDM2.  MDM2 is a negative regulator of p53 that targets p53 for degradation 
through ubiquitinization.  AKT mediated phosphorylation of MDM2 allows MDM2 to 
translocate more efficiently to the nucleus, resulting in enhanced degradation of p53 (Zhou 
et al., 2001).  AKT is also known to function in cell survival by directly phosphorylating 
pro-apoptotic proteins, such as BAD and caspase- 9 (Datta et al., 1997; Cardone et al., 
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1998).  Because of the close connection between AKT and p53, it is possible to suspect 
that mutant p53 mediates the activity of AKT and its role in cell survival.  To explore this 
possibility, we used the Ponasterone A- inducible mutant p53 R175H.  We observed the 
expression of phosphorylated AKT and the total amount of AKT increased over time up to 
96 hours in Ponasterone A induced cells.  However, cells in the absence of Ponasterone A 
also showed increase in phosphorylated AKT and total AKT expression as well.  Further 
study using the control cell line showed that phosphorylated AKT and total AKT 
expression increased over time in both induced and uninduced control cells.  It has been 
documented that mutant p53 induces AKT phosphorylation in endometrial cell using the 
R175H mutant (Dong et al., 2009). However, our studies indicated that the 
phosphorylation of AKT is independent of mutant p53 R175H or Ponasterone A in H1299 
lung cancer cells.   
 
NFκB Promotes Cell Motility in Cells Expressing p53 Mutants 
NFκB has been suggested to play a role in regulation of apoptosis, invasion, and 
angiogenesis in tumor cells (Lee et al., 2007).  Previous studies have shown that tumor 
derived p53 mutants can induce NFκB2 gene expression (Scian et al., 2005).  It is also 
known that NFκB regulates the transcription of diverse genes encoding cytokines, growth 
factors, and cell adhesion molecules (Lodish, 2004).   Studies have shown that NFκB plays 
a substantial role in EMT and promotes cell migration and invasiveness (Tobar, 2010).  
During EMT, cancer cells lose expression of proteins that promotes cell-to-cell adhesion 
such as E-cadherin, acquire mesenchymal markers such as vimentin, and increase protease 
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expression to allow cells to enhance their ability for migration and invasion (Min et al., 
2008). One of the key responses in EMT is ECM degradation (Thiery, 2002), which is one 
of the hallmarks of tumor invasiveness (Hanahan and Weinberg, 2000).  MMP-9 and uPA 
are two classes of proteases that are involved in ECM degradation and have been 
implicated as a critical requirement in tumor spreading during metastasis (Kim et al., 
1998).  It has been indicated that TGF-β induces proteases by ROS-mediated NFκB 
activation (Tobar et al., 2010).  NFκB acts as transcriptional factor for MMP-9 and uPA 
which possess NFκB elements in their promoter regions (Reuning et al., 1999; Yan and 
Boyd, 2007). In addition, NFκB represses expression of the tumor suppressor maspin, 
which inhibits uPA activation and metastasis (Luo et al., 2007). Our goal was to determine 
whether NFκB contributes to increased cell motility in mutant p53 cell lines.  Our scratch 
assay results show that cells incubated in the presence of the NFκB inhibitor had decreased 
motility compared to controls without NFκB inhibitor.  This indicates that gain-of-function 
mutant p53 effects on cell motility are due in part to the enhanced NFκB activity.        
 
Inhibition of AKT or NFκB Reduce CXCL5-Chemokine Expression 
Chemokines functions mainly as chemoattractants for leukocytes, monocytes, 
neutrophils, and other effector cells (Gerber et al., 2009).  The secretion of the chemokines 
and the cell surface expression of the chemokine receptors on tumor cells play critical roles 
in facilitation of tumor growth and/ or metastasis.  Evidence suggests that ELR
+
 CXC 
chemokines, such as CXCL5 and CXCL8, stimulate cell migration, proliferation, and 
angiogenesis (Raman et al, 2007).  It was also suggested that the ELR
-
 chemokine 
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CXCL12 and its receptor CXCR4 both play an important role in metastatic progression 
(Orimo and Weinberg, 2006).  Previous studies have shown that CXC chemokines, such as 
CXCL5, CXCL8, and CXCL12, can be upregulated by mutant p53 protein. Inhibition of 
CXCL5 reduces cell motility in mutant p53 expressing cell (Yeudall et al., submited). Our 
studies suggest that AKT and NFκB also play a role in cell motility.  Inhibition of AKT or 
NFκB decreases cell motility in gain-of-function mutant p53 expressing cells.  We also 
investigated the effects of AKT and NFκB on CXCL5 expression in cells expressing 
mutant p53.   QRT-PCT results indicate that induced cell motility by AKT or NFκB may 
be mediated, in part, by increased CXCL5 expression.  Previous studies have shown that 
expression of CXCL5 in vector control cells is low compared to gain-of-function mutant 
p53 cells (Yeudall et al., submitted), however here our data showed that the CXCL5 
expression is higher.  We suspect that high expression of CXCL5 in vector control is due 
to DMSO that was used as a solvent.  Further studies can be performed comparing CXCL5 
expression of cells in the presence and absence of DMSO in vector control cells. 
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Future studies 
 In this study, we have shown that gain-of-function mutant p53 can induce cell 
motility.  We also showed that AKT and NFκB play roles in cell motility in gain-of-
function mutant p53 expressing cells.  Inhibition of AKT or NFκB reduced cell motility in 
cells expression mutant p53.  Regulation of cell motility by AKT and NFκB are, in part, 
mediated by CXCL5-chemokines.  To confirm the effects of AKT and NFκB on CXCL5 
expression, luciferase reporter assays can be performed to determine chemokine promoter 
activity in the presence and in absence of inhibitors.   We can also expand the motility 
study by using CXC5-chemokine knock down or over expressed cells in presence and 
absence of inhibitors. 
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